)
ImmuCell (ICCC) investor relations material
ImmuCell Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Revenue for Q2 2026 increased 11.5% year-over-year to $7.2 million, driven by higher sales volumes, price increases, and strong demand for First Defense®, with expanded market share and investments in leadership, sales, and manufacturing.
Net income for Q2 2026 rose to $1.8 million (25.5% margin), up from $0.5 million, aided by a $2 million legal settlement from a former contract manufacturer.
Distributor out-the-door volume grew 28% in Q2 2026, with Tri-Shield® and Functional Feed lines contributing to growth.
Commercial results benefited from restored product availability, expanded commercial team, and favorable domestic calf market conditions.
The company is executing a two-phase manufacturing expansion to triple capacity, with $8 million in planned investments over 18 months.
Financial highlights
Six-month revenue increased 20.9% year-over-year to $17.5 million; Q2 2026 product sales were $7.2 million, up from $6.4 million.
Gross margin declined to 33.9% from 43.7% in Q2 2025, mainly due to higher costs, lower output, and cost shifts.
Net income for the first six months was $3.8 million, nearly doubling year-over-year.
Adjusted EBITDA for Q2 2026 was $2.7 million, up from $1.4 million; six-month adjusted EBITDA was $5.4 million.
Cash and cash equivalents increased to $8.9 million as of June 30, 2026, from $3.8 million at year-end 2025; stockholders’ equity rose to $31.4 million.
Outlook and guidance
Capacity expansion projects totaling $8 million are expected to be completed in phases through 2027, aiming to triple capacity and improve costs.
Focus on yield improvement, cost management, and reliable supply to support scalable growth.
Ongoing investments in manufacturing are expected to support future demand growth for First Defense®.
No pending plans to issue additional shares under the ATM equity program as of June 30, 2026.
The company anticipates continued tax liability as NOLs now offset only 80% of taxable income.
- Strong growth, market share gains, and financial recovery position First Defense® for expansion.ICCC
Investor presentation - Record sales and margin growth position First Defense® for continued market share gains.ICCC
Investor presentation - All proposals passed and a major manufacturing expansion was announced to support growth.ICCC
AGM 2026 - First Defense® gains share in a growing market, fueling record sales and margin expansion.ICCC
Investor presentation - Record Q1 2026 sales and net income growth fueled by margin gains and strong cash flow.ICCC
Q1 2026 - Shareholders will vote on board elections, compensation, new equity plan, officer exculpation, and auditor approval.ICCC
Proxy filing - Double-digit growth, rising market share, and financial recovery fuel expansion in scours prevention.ICCC
Investor presentation - Full-year sales up 4.3% as Tri-Shield® growth and First Defense® focus offset declines.ICCC
Q4 2025 TU - Record Q1 sales, margin gains, and net income highlight strong growth and operational recovery.ICCC
Q1 2025
Next ImmuCell earnings date
Next ImmuCell earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage